Intravitreal Injection

An intravitreal injection delivers medication directly into the vitreous gel of the eye to treat retinal diseases that cause abnormal blood vessel growth or fluid leakage, such as age-related macular degeneration and diabetic macular oedema. Anti-VEGF drugs are the most commonly injected medications, working to shrink abnormal blood vessels and reduce retinal swelling. Because the medication is delivered directly to the site of disease, it is far more effective than oral or topical treatment for these conditions. Most patients require a series of repeated injections over months to years to maintain the treatment effect.

Intravitreal Injection is recommended for patients diagnosed with specific conditions where other approaches have been insufficient. Your Ophthalmology specialist will assess your suitability based on your diagnosis, health history, and treatment goals.

The typical duration is 5-10 minutes. This may vary based on the complexity of your case and individual response to treatment.

Recovery typically takes Most patients resume normal activities the same day, with mild redness or soreness resolving within a day or two. Repeat injections are typically scheduled every 4-8 weeks initially, tapering based on the eye's response to treatment.. Your care team will provide specific instructions based on your response and overall health.

Side effects vary by individual and are detailed in the section above. Your specialist will discuss all risks and benefits with you before treatment begins. Serious adverse effects are uncommon but are part of the informed consent process.

Intravitreal Injection has a documented success rate of 80-85% at accredited facilities. Outcomes depend on disease stage, patient health, and adherence to the treatment plan and aftercare instructions.